Could a patent ruling threaten Moderna’s Covid-19 vaccine?
Update: Moderna released an updated statement Friday afternoon saying that the LNPs used in its Covid-19 vaccine, mRNA-1273, are not part of the disputed intellectual property. “Moderna is not aware of any significant intellectual property impediments for any products we intend to commercialize, including mRNA-1273,” they said.
For years, Moderna has been battling a tiny Pennsylvania biotech over patents for a technology required to deliver its mRNA drugs and vaccines. Yesterday, a ruling came down at what might be the most inopportune time for Moderna, potentially delaying their Covid-19 vaccine or cutting into the potential profits that quintupled their stock in less than 5 months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.